34208297|t|Biphenylalkoxyamine Derivatives-Histamine H3 Receptor Ligands with Butyrylcholinesterase Inhibitory Activity.
34208297|a|Neurodegenerative diseases, e.g., Alzheimer's disease (AD), are a key health problem in the aging population. The lack of effective therapy and diagnostics does not help to improve this situation. It is thought that ligands influencing multiple but interconnected targets can contribute to a desired pharmacological effect in these complex illnesses. Histamine H3 receptors (H3Rs) play an important role in the brain, influencing the release of important neurotransmitters, such as acetylcholine. Compounds blocking their activity can increase the level of these neurotransmitters. Cholinesterases (acetyl- and butyrylcholinesterase) are responsible for the hydrolysis of acetylcholine and inactivation of the neurotransmitter. Increased activity of these enzymes, especially butyrylcholinesterase (BuChE), is observed in neurodegenerative diseases. Currently, cholinesterase inhibitors: donepezil, rivastigmine and galantamine are used in the symptomatic treatment of AD. Thus, compounds simultaneously blocking H3R and inhibiting cholinesterases could be a promising treatment for AD. Herein, we describe the BuChE inhibitory activity of H3R ligands. Most of these compounds show high affinity for human H3R (Ki < 150 nM) and submicromolar inhibition of BuChE (IC50 < 1 microM). Among all the tested compounds, 19 (E153, 1-(5-([1,1'-biphenyl]-4-yloxy)pentyl)azepane) exhibited the most promising in vitro affinity for human H3R, with a Ki value of 33.9 nM, and for equine&nbsp;serum BuChE, with an IC50 of 590 nM. Moreover, 19 (E153) showed inhibitory activity towards human MAO B with an IC50 of 243 nM. Furthermore, in vivo studies using the Passive Avoidance Task showed that compound 19 (E153) effectively alleviated memory deficits caused by scopolamine. Taken together, these findings suggest that compound 19 can be a lead structure for developing new anti-AD agents.
34208297	0	31	Biphenylalkoxyamine Derivatives	Chemical	-
34208297	32	53	Histamine H3 Receptor	Gene	11255
34208297	67	88	Butyrylcholinesterase	Gene	590
34208297	110	136	Neurodegenerative diseases	Disease	MESH:D019636
34208297	144	163	Alzheimer's disease	Disease	MESH:D000544
34208297	165	167	AD	Disease	MESH:D000544
34208297	592	605	acetylcholine	Chemical	MESH:D000109
34208297	782	795	acetylcholine	Chemical	MESH:D000109
34208297	886	907	butyrylcholinesterase	Gene	590
34208297	909	914	BuChE	Gene	590
34208297	932	958	neurodegenerative diseases	Disease	MESH:D019636
34208297	971	985	cholinesterase	Gene	590
34208297	998	1007	donepezil	Chemical	MESH:D000077265
34208297	1009	1021	rivastigmine	Chemical	MESH:D000068836
34208297	1026	1037	galantamine	Chemical	MESH:D005702
34208297	1079	1081	AD	Disease	MESH:D000544
34208297	1123	1126	H3R	Gene	11255
34208297	1193	1195	AD	Disease	MESH:D000544
34208297	1221	1226	BuChE	Gene	590
34208297	1250	1253	H3R	Gene	11255
34208297	1310	1315	human	Species	9606
34208297	1316	1319	H3R	Gene	11255
34208297	1366	1371	BuChE	Gene	590
34208297	1427	1431	E153	Chemical	-
34208297	1433	1477	1-(5-([1,1'-biphenyl]-4-yloxy)pentyl)azepane	Chemical	-
34208297	1530	1535	human	Species	9606
34208297	1536	1539	H3R	Gene	11255
34208297	1577	1594	equine&nbsp;serum	Species	
34208297	1595	1600	BuChE	Gene	590
34208297	1640	1644	E153	Chemical	-
34208297	1681	1686	human	Species	9606
34208297	1687	1692	MAO B	Gene	4129
34208297	1804	1808	E153	Chemical	-
34208297	1833	1848	memory deficits	Disease	MESH:D008569
34208297	1859	1870	scopolamine	Chemical	MESH:D012601
34208297	1976	1978	AD	Disease	MESH:D000544
34208297	Association	MESH:D019636	590
34208297	Negative_Correlation	MESH:D005702	590
34208297	Negative_Correlation	MESH:D005702	MESH:D000544
34208297	Negative_Correlation	MESH:D000068836	590
34208297	Negative_Correlation	MESH:D000068836	MESH:D000544
34208297	Negative_Correlation	MESH:D000077265	590
34208297	Negative_Correlation	MESH:D000077265	MESH:D000544
34208297	Positive_Correlation	MESH:D012601	MESH:D008569
34208297	Negative_Correlation	11255	590

